 Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 GLOBE NEWSWIRE Palisade Bio, Inc. Nasdaq: PALI, a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal GI complications the Company, today announced that holders of an additional 1.46 million common stock purchase warrants ... The post Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting... 